Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,003.67 +1.94 (+0.19%)
Streaming Delayed Price Updated: 11:32 AM EDT, Jun 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients
Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid... 
Via Benzinga
Delta, Lambda Covid Variants Still Weighing On Market Despite Positive Earnings Reports
The market is still in a waiting mode, with a lot hinging on tomorrow’s jobs report. Predictions of a volatile, choppy week in the equity markets did not disappoint on... 
Via Benzinga
Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer
The Phase 3 trial of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo in combination with platinum-doublet chemotherapy... 
Via Benzinga
Regeneron Beats Street Estimates Big In Q2 As COVID-19 Antibody Boosts Topline, Cuts FY21 R&D Spend Outlook
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned $25.80 per share for the second quarter, beating the $17.69 estimate. It clocked revenue of $5.1 billion,... 
Via Benzinga
Exposures COVID-19
Regeneron Pharmaceuticals: Q2 Earnings Insights
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 0.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share... 
Via Benzinga
Regeneron Earnings Obliterate Views; Biotech Giant Tops Buy Point
Regeneron earnings and sales boomed far above forecasts. The biotech giant rose above a buy point. 
Via Investor's Business Daily
3 Biotech Stocks That Could Make You Richer in August (and Beyond)
All three have blockbuster products already on the market. 
Via The Motley Fool
Market Briefing For Tuesday, Aug. 3
We do see Tuesday turnaround as a rebound from Monday's just modest fade. Again our wildcard continues to be Covid; and the 'presumed' dovish Fed as relates to 'tapering'. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
10 Biggest Price Target Changes For Monday
Raymond James raised Edwards Lifesciences Corporation (NYSE: 
Via Benzinga
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
Following the June update that 
Via Benzinga
Exposures COVID-19 Product Safety
Market Briefing For Monday, Aug. 2
We're 'not' in a global financial crisis; but we are failing the 'synchronized global recovery', due to the worldwide pandemic. 
Via Talk Markets
Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (... 
Via Benzinga
Is This Mid-Cap Biotech Stock a Buy Now?
This mid-cap growth stock could be a long-term winner. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Market Briefing For Thursday, July 29
Disarming SARS-CoV-2 with pharmaceutical drugs is the 'holy grail' to end the COVID-19 panic, and generally eliminate the panic pressures for vaccines. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
3 Things About Regeneron That Smart Investors Know
The biotech's COVID-19 antibody cocktail made headlines last year, but there's a bigger story here. 
Via The Motley Fool
Topics Government
Exposures COVID-19 Political
3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap. 
Via The Motley Fool
Maravai Lifesciences Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Maravai Lifesciences sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all... 
Via Benzinga
Alnylam Pharmaceuticals Stock Sees Healthy Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alnylam Pharmaceuticals stock climbed into a new percentile Monday, as it got a lift from 63 to 71. 
Via Investor's Business Daily
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
C4 Therapeutics Stock Enters Leadership Territory
A Relative Strength Rating upgrade for C4 Therapeutics shows improving technical performance. 
Via Investor's Business Daily
AMD And Biogen Lead The QQQ Lower Thursday
U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell’s comments on inflation to the Senate banking panel. ... 
Via Benzinga
Topics Economy
Exposures Interest Rates
5 French Stocks To Consider For Bastille Day
Bastille Day is France’s National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept... 
Via Benzinga
Is This Coronavirus Stock Undervalued?
This biotech giant might be down, but it isn't out just yet. 
Via The Motley Fool
Exposures COVID-19
2 Biotech Stocks That are Dirt Cheap Right Now
Biotech companies responded to the COVID-19 pandemic in a remarkable way, with vaccinations, treatments, diagnostics, and variant monitoring. 
Via Talk Markets
Exposures COVID-19
3 Top Biotech Stocks to Buy in July
Now's the time to get into these companies while their valuation is still favorable. 
Via The Motley Fool
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher? 
Via The Motley Fool
Here's Why Regeneron Gained 11% Last Month
The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands. 
Via The Motley Fool
Will an Increase in Vaccinations Hurt Regeneron's COVID Treatment Sales?
The antibody cocktail treats people with mild-to-moderate illness. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.